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The COVID-19 pandemic has affected more than 125 million lives worldwide 
and more than 2.5 million people have died so far. Cancer in itself increases the risk 
of infection especially, cancer patients undergoing cancer-associated treatments 
are more susceptible to SARS-CoV2 infection. However, many questions related 
to the biological interconnection between the two diseases remain to be answered. 
This chapter summarizes some of the biological components that connect cancer 
to COVID-19 and provide knowledge to not only understand but also, target the 
co-morbidities.
Keywords: COVID-19, cancer, viral infections, chemotherapy, radiotherapy, 
immunotherapy, cytokine storm, coagulopathy, ACE2, TMPRSS2
1. Introduction
For past many decades, viral infections have presented a great challenge for 
cancer patients, on the delivery of cancer care, cancer research, and oncologists. 
COVID-19 caused by SARS-CoV2 virus continues to spread around the globe and 
more than 1 million people have been killed due to COVID-19 worldwide (at the 
time of writing). Though majority of infected people will recover, cancer patients 
remain at a higher risk to SARS-CoV2 infection and its related severe outcomes. 
Cancer patients are reported ~3 times more susceptible to SARS-CoV2 infection 
with possible poor outcomes than individuals without cancer potentially due to 
their systemic immunosuppressive state caused either by malignancy itself or the 
anti-cancer treatments. Moreover, the mortality rate of SARS-CoV2 positive cancer 
patients was reported 6% than 1% for non-cancer patients in China. However, 
a limited research has been done to understand the biological interconnection 
between cancer and viral infections. Especially, little is known about the SARS-
CoV2 infection biology Therefore, studying whether and how SARS-CoV2 affects 
cancer and its progression and, vice versa is of utmost importance for (1) the better 
management of SARS-CoV2 infected cancer patients and, (2) developing novel 
treatment strategies that can target SARS-CoV2 and/or cancer.
2. Linking viruses and cancer
Viruses are the smallest microorganisms made up of a small number of genes 
in the form of DNA or RNA surrounded by a protein coating. Viruses enter into a 
living cell and hijack it’s cellular machinery in order to make more copies of itself. 
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When a virus enters the body, it triggers the body’s immune system. These immune 
defenses begin with white blood cells which learn to attack and destroy the virus or 
the virus infected cells. If the body survives the virus attack, the immune system’s 
memory is able to respond more quickly and effectively to subsequent infection by 
the same virus. This response is called Immunity. Immunity can also be triggered 
by getting a vaccine. Viruses can be divided into three classes: oncogenic, oncolytic 
and, non-oncogenic non-oncolytic viruses. The oncogenic viruses (for example, 
hepatitis C virus, human T-lymphotropic virus, hepatitis B virus) change cells by 
either integrating their genetic material with the host cell’s DNA or enhancing 
already existing oncogenic genes within the host genome. Thus, the infected cell 
is regulated by the viral genes and has the ability to undergo abnormal growth. 
Conflicting results for the relationship between different viruses and various 
cancer sub-types have been stated in pre-clinical and clinical settings. This is due 
to the reason that the course and outcome for both, viral infections and cancer and 
regulated by the type of viral infection, type of cancer and the immune system 
components involved. For example, a faster growth of melanoma was observed in 
mice that were challenged with H1N1/influenza A virus due to shunting or diversion 
of cytotoxic T cells from tumor site to the viral infection site. On the contrary, a 
slower growth of Lewis lung carcinoma cells was observed in mice following influ-
enza virus infection. Thus, more studies need to be undertaken for clearer context 
dependent results. Both viruses and cancer invade our normal healthy systems for 
their growth and proliferation. The inability of our immune system to distinguish 
between self and non-self, links the severe pathogenesis associated with cancer and 
viral infections.
3. COVID-19
Coronaviruses are a large family of viruses that can cause mild illnesses, such 
as the common cold, to more severe diseases such as Severe Acute Respiratory 
Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Coronaviruses 
take their names from the distinctive spikes with rounded tips around their surface, 
which reminded virologists of the appearance of the sun’s atmosphere, known as 
corona. Coronaviruses are known to primarily target the human respiratory system. 
COVID-19 represents the seventh member of the coronavirus family that infects 
humans. Because the novel coronavirus is related to the SARS-associated coronavi-
rus (SARS-CoV), the virus has been named SARS-CoV2. SARS-CoV2 infection may 
result in mild to severe symptoms that may develop between 2 and 14 days after 
exposure to the SARS-CoV2 virus. The symptoms of COVID-19 may include short-
ness of breath, chills, fever, cough, headaches, sore throat, and loss of taste or smell. 
Additional symptoms including aches, fatigue, nasal congestion and diarrhea may 
also appear. The illness may cause severe pneumonia and heart problems in some 
people and may also lead to death. Some people may not develop any symptoms 
following infection.
SARS-CoV2, by using the spike-like protein on its surface, binds to ACE2 
(Angiotensin converting enzyme 2) prior to entry and infection into the host 
cell. Thus, ACE2 acts as a doorway for the virus that causes COVID-19. ACE2 is a 
carboxypeptidase enzyme present on the surface of many cell types in tissues like, 
lungs, heart, blood vessels, kidneys, liver and gastrointestinal tract. The function of 
ACE2 is to generate small peptides/proteins by cutting up the larger protein angio-
tensin which then go on to regulate functions in the cells involving wound healing, 
inflammation and blood pressure regulation, etc.
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4. Cancer
Cancer is a broad term for a class of diseases characterized by uncontrolled growth 
and proliferation of abnormal cells. These normal cells have the ability to infiltrate 
and destroy normal tissues. The types of treatments that one receives depend on the 
type of cancer and how advanced it is. Mostly it is a combination of treatments such 
as chemotherapy, radiotherapy, immunotherapy, hormonal therapy, stem cell trans-
plantation and other targeted therapies. Cancer on its own and its treatment using 
chemotherapy or radiotherapy weakens one’s immune system, reducing the number 
of infections fighting immune cells and making it harder for one’s body to fight infec-
tions including the viral infections. And this is why cancer patients who are undergo-
ing or recently underwent chemo/radiotherapy are particularly at higher risk.
5. COVID-19 and cancer
COVID-19 by itself remains biologically novel and not much is known about the 
role of novel coronavirus SARS-CoV2 in cancer. Some critical questions that need 
to be answered are (1) Whether SARS-CoV-2 infection cause cancer? (2) Whether 
SARS-CoV-2 infection increases the risk of cancer? and, (3) Whether SARS-CoV-2 
infection affects the survival of cancer patients?
Similar to other severe acute respiratory outbreaks (SARS-CoV, MERS-CoV), 
comorbidities such as hypertension and malignancy predispose COVID-19 positive 
patients to adverse clinical outcomes [1–4]. Whether SARS-CoV2 causes or modu-
lates cancer pathobiology, is unknown. However, it is evident that patients undergo-
ing cancer-associated treatments for example, chemo or radiotherapy and CAR-T cell 
therapy patients are at higher risk of becoming worse following COVID-19 infection 
[5, 6]. A recent study including 1,590 COVID-19 positive patients in China shows 
cancer as one of the more serious comorbidities that increase risk with respect to 
COVID-19 [4, 7]. Therefore, cancer patients receiving anti-tumor therapies should 
have vigorous screening for COVID-19 infection and their immunosuppressive 
treatment regimens and dosages potentially decreased in the case of COVID-19 co-
infection [8]. For some patients, chemotherapy must be postponed until completion 
of the antiviral course of therapy, while others cannot be subjected to the viral infec-
tion therapy while under treatment for their cancer [9]. The symptoms of COVID-19 
in cancer patients are mostly similar to the ones in general population (fever, cough-
ing and shortness of breath) [10, 11]. However, cancer-associated treatments for 
example, steroids may suppress the fever symptom of COVID-19. The decision on 
treatment of a COVID-19 positive cancer patient depends on the type of cancer, stage 
of treatment, and severity of COVID-19. Immune dysregulation and chronic inflam-
mation may be potential drivers of severe outcomes in COVID-19-positive cancer 
patients. Therefore, a better understanding of the mechanistic link between the two 
will help to prevent negative effects of infection and also enable the design of novel 
therapies that target cancer and COVID-19, and co-target both diseases.
6. The biology of interconnection between COVID-19 and cancer
The biological connection between COVID-19 and cancer remains an under-
studied area. However, age, ACE2, cytokine storm, and coagulopathy are few strong 
connecters that link COVID-19 with cancer. A better understanding of these linkers 
may help us find novel therapy options for the comorbidities.
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6.1 Age
Our risk of getting cancer increases with age mostly due to accumulation of 
mutations with our prolonged exposure to mutagens. In addition, as we grow older, 
our body’s immune system and DNA damage repair system get weaker [12]. In a 
similar fashion, age has turned out to be a poor prognostic factor for COVID-19 
patients. This suggests that age plays a similar role in the progression and pathogen-
esis of cancer and COVID-19. Further studies should be conducted to identify the 
molecular interconnection between age, cancer and COVID-19.
6.2 Angiotensin converting enzyme 2 (ACE2)
ACE2 is a carboxypeptidase enzyme that converts angiotensin I to angiotensin 
1–9 and angiotensin II to angiotensin 1–7. It is involved in the regulation of heart 
function and in the protection during acute lung injury [13–15]. SARS-CoV-2 enters 
human cells through angiotensin 1 converting enzyme 2 (ACE2) [16, 17]. The virus 
enters via this spike protein, binds to ACE2, and together with ACE2 enters the cell, 
fuses to the membrane, the virus exists the endosome, and replicates [18]. ACE2 
is expressed in multiple organs, including cardiovascular, respiratory, urinary and 
digestive systems in healthy individuals. The expression levels of ACE2 in cellular 
subtypes is shown to be viral infection- and interferon-driven [19–21]. Notably, the 
expression levels of ACE2 are different in cancer cells. According to a recent clini-
cal study, the expression levels of ACE2 gradually increase from healthy control, 
adenoma, to colorectal cancer patients. This indicates that cancer patients are more 
likely to be infected with SARS-CoV2. Patients with tumors, expressing higher lev-
els of ACE2, are more susceptible to SARS-CoV2 infection and have poor prognosis 
[19, 22, 23]. Renal tissue shows higher expression levels of ACE2, and this might 
explain why most COVID-19 patients have renal dysfunction [18, 24]. Decreased 
levels of ACE2 were reported in non-small cell lung cancer (NSCLC), and its over-
expression had a protective effect in NSCLC and breast cancer via inhibiting cell 
growth and angiogenesis [25–27]. Due to limited research done in this area, it would 
be worthwhile to test whether levels of ACE2 increases or decreases in various 
tissues of cancer patients and COVID-19 patients and how this impacts COVID-19 
infection in these patients.
6.3 Cytokine release syndrome
Cytokine release syndrome (CRS) or cytokine storm is a systemic inflam-
matory response. Cytokine storm can be triggered by pathogenic infections, 
certain drugs, antibody treatments and, chimeric antigen receptor (CAR)-T cell 
therapy [28, 29]. Cytokine storm induction is the main cause of inflammation 
in SARS-CoV-2 infection. Upregulation of cytokines for example, interleukin-6 
(IL-6), interleukin-1 beta (IL-1β) in serum, tumor necrosis factor-alpha (TNF-α) 
are found in COVID-19 patients. Elevated levels of lactate dehydrogenase, and 
increased levels of circulating monocytes are also common in COVID-19 patients 
[30, 31]. Such elevated levels of pro-inflammatory cytokines are also observed 
in cancer patients undergoing immunotherapy and CAR-T cell therapy [32]. The 
cytokine levels in cancer patients undergoing immunotherapy are higher than the 
cytokine levels in COVID-19 patients experiencing acute respiratory disease syn-
drome. The understanding of oncologists in regulating severe inflammatory reac-
tion may prove highly beneficial in these settings. Therefore, anti-inflammatory 
therapies currently used for cancer patients may be repurposed for the treatment 
of COVID-19 patients.
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6.4 Coagulopathy
Bleeding complications including thrombosis are leading causes of death in 
cancer patients. Thrombotic events are also commonly associated with the morbidi-
ties in COVID-19 patients. Cancer/tumor cells release cytokines, cysteine proteases, 
tumor micro particles and other pro-coagulants in their microenvironment. Release 
of such biomolecules can cause an imbalance in hemostasis [33]. Increased levels of 
D-dimer and prothrombin and decrease in fibrinogen is reported in COVID-19 non-
survivor patients at days 10–14 [34–36]. This highlights the significance of regular 
monitoring and maintenance of these factors in COVID-19 and cancer patients. 
Therefore, further insights into the molecular interconnections of COVID-19 and 
cancer disease conditions to coagulopathy may help in reducing the associated 
mortality in these patients.
6.5 TMPRSS2
Transmembrane Serine Protease 2, TMPRSS2 presents another potential point 
of connection between cancer and COVID-19. In prostate cancer TMPRSS2 is 
regulated by the androgen receptor, and the androgen receptor is found not only 
on prostate cells but on cells of the lung as well. Further investigation is needed 
to confirm whether the receptor regulates TMPRSS2 in lung tissue, but if it does, 
androgen-targeted therapies, which are used in the treatment of prostate cancer, 
could limit SARS-CoV2 infection by downregulating TMPRSS2.
7. Therapeutic options in COVID-19 and cancer patients
Previous studies suggest conflicting results on whether anti-cancer and anti-
COVID-19 therapies can be co-administered safely. For example, in over 1000 
HCV-positive breast cancer patients, chemotherapy was shown feasible with no sig-
nificant side effects [37]. However, in another study, ovarian cancer patients under-
going chemotherapy were unable to generate antibody response to the influenza 
vaccination [38]. Therefore, further efforts are needed to investigate the efficacy 
and safety of co-administration of anti-cancer and anti-viral drugs and how these 
outcomes are dependent on the type of cancer, viral infection and therapy.
Vaccination is the most promising approach for preventing a viral infection. 
Pharmaceutical industries and research organizations across the globe have put 
great efforts in developing effective and novel vaccine candidates to neutralize 
SARS-CoV2 virus. Additionally, strategies like repurposing direct preexisting anti-
viral drugs as well as convalescent serum from COVID-19 recovered patients have 
been effectively used. Different monoclonal antibodies (mAbs) that recognize the 
different epitopes on the viral surface may have improved efficacy in neutralizing 
the SARS-CoV2 virus. IL-6 inhibitors (for example, tocilizumab and siltuximab 
mAbs) have been used for the management of cytokine storm in cancer patients 
receiving CAR-T cell therapy. IL-1, a cytokine upstream of IL-6 which is also 
upregulated in CRS and IL-1 receptor antagonists such as anakinra have been used 
to treat arthritis patients. Another class of drugs are nontoxic immune-suppressants 
known as calcineurin inhibitors that impair T-cell function and thereby reduce 
cytokine levels. Various viral gene components fundamental for the unchecked pro-
liferation of virus in host cancer cells can serve as therapeutic targets for effective 
anti-viral therapies. Studying these critical viral components will help the research-
ers to understand the interconnection between the biology of COVID-19-infected 
cancer versus normal host cells.
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Figure 1. 
Interconnection between COVID-19 and cancer.
The role of various immune cells for example, T cells, and natural killer (NK) 
cells in understanding the pathology and therapies of cancer and viral infections 
is becoming more evident with time. This motivates scientists to enhance their 
understanding and develop novel immunomodulatory therapeutic strategies 
for co-targeting these diseases. Functional natural killer (NK) cells can produce 
antiviral responses against influenza infection and are also reported as potential 
anti-cancer agents. Additionally, due to their negligible graft vs. host signature, 
NK cells may provide a safer alternative to co-target cancer and COVID-19. 
Nanoparticles present excellent vehicles for delivering various disease-associated 
payloads in vivo. Nanoparticles ornated with recombinant human ACE2 protein on 
their surface may provide an effective therapeutic option for COVID-19 patients. 
Following binding to the spike protein of SARS-CoV2 virus, ACE2-conjugated 
nanoparticles may neutralize the virus and prevent it from binding to the ACE2 
receptor present on host cells. Conventional anti-cancer treatment strategies, 
such as chemo or radiotherapy are unable to distinguish between cancer cells and 
normal cells. This is a significant drawback and leads to toxicities for patients 
undergoing treatment. Therapies that directly target viral proteins or generate 
immune responses against infected cells or cancer cells hold promise for effective 
and tolerable treatment strategies.
8. Future research perspectives
To understand the pathogenesis of COVID-19 and to connect the link between 
cancer and COVID-19, we need to develop and study suitable animal models that 
represent the comorbidity of different cancers and COVID-19 in patients with 
accuracy. Additionally, the role of specific SARS-CoV2 proteins may be studied by 
developing chimeric mouse models that express SARS-CoV2 proteins in some tis-
sues. Ziegler et al. demonstrated that ACE2 expressing human cells are the primary 
targets for SARS-CoV2 infection and that human ACE2 expression in epithelial cells 
is interferon dependent [20]. Especially, a significantly weaker induction of murine 
ACE2 was observed in response to interferon or viral infection [20]. Thus, human-
ized models permissive to SARS-CoV2 infection would closely mimic the human 
disease condition. Investigating and identifying the relevant immune constituents 
may lead to new biological strategies to target co-morbidities associated with viral 
infections and cancer patients. Determining whether active SARS-CoV2 virus leads 
to cancer in mice would also be an interesting scientific to avenue to better under-
stand the pathology of SARS-CoV2. Clearly, the learnings from cancer biology and 
cancer therapeutics research will help in establishing clinically effective treatment 
options for COVID-19 patients (Figure 1). It would also be of high relevance to 
include and study the role of demographic factors in context of cancer and COVID-
19 comorbidities.
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